Clinical and demographic characteristics related to tumour response
| Correlation with complete tumour response | |||
|---|---|---|---|
| Clinical and demographic characteristics | n±SD (%) | Univariate analysis | Multivariate analysis |
| Age (years) | 68±8.4 | NS | NS |
| Gender | NS | NS | |
| Male | 26 (63) | ||
| Female | 15 (36) | ||
| Race | |||
| Non-Hispanic white | 38 (93) | NS | NS |
| Hispanic | 2 (5) | ||
| Black | 1(2) | ||
| Eye | NS | NS | |
| Right eye (%) | 21 (51) | ||
| Left eye (%) | 20 (48) | ||
| Thickness > 1.5 mm | 10 (24) | 0.005 | 0.045 |
| Fornix involvement | 12 (29) | 0.015 | NS |
| Tarsal involvement | 7 (17) | 0.009 | NS |
| Multifocality | 9 (22) | 0.002 | 0.023 |
| Limbus involvement (in clock hours) | 3.9±1.8 | NS | NS |
| Largest basal diameter (mm) | 8.7±4.8 | 0.059 (NS) | NS |
| AJCC staging system* | 0.028 | NS | |
| T1 | 10 (24) | ||
| T2 | 19 (46) | ||
| T3 | 12 (29) | ||
| Histopathology | 0.019 | NS | |
| Low-grade dysplasia | 20 (48) | ||
| High-grade dysplasia | 13 (31) | ||
| Squamous cell carcinoma | 8 (19) | ||
Bold values are statistically significant.
*AJCC staging system: T1 (tumour ≤5 mm in greatest dimension); T2 (tumour >5 mm in greatest dimension, without invasion of adjacent structures) and T3 (tumour invades adjacent structures, excluding the orbit).
AJCC, American Joint Committee on Cancer, NS, non-significant.